IFNA1 and myeloid sarcoma: The proportion of R-MS patients without new or enlarging T2 lesions was 61.7% and 60.9% in the ocrelizumab groups, and 38.7% and 38% in the IFN groups (p<0.001), whereas the proportion of cases without gadolinium-enhancing lesions was 91.7% and 90.2% in the ocrelizumab groups and 69.8% and 63.9% in the IFN groups (p<0.001) (59).